CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- CytoSorbents
Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2023
operating and financial results after the market close on Thursday, November 9th, 2023. CytoSorbents’ management will host a live presentation webcast and a question and answer session at 4:30PM
EDT the same day.
Webcast Details:
Date: Thursday, November 9th, 2023
Time: 4:30 PM Eastern
Webcast link: https://edge.media-server.com/mmc/p/9egdsb9a
Conference ID 5576338
Participant Dial-In:
United States - New York +1.646.968.2525
USA & Canada - Toll-Free +1.888.596.4144
It is recommended that participants dial in approximately 10 minutes prior to the start of the call.
An archived recording and written transcript of the conference call will be available under the Investor Relations section of the Company’s website at https://ir.cytosorbents.com/.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb, is approved in the European Union and distributed in 75 countries worldwide with more than 212,000 devices cumulatively used as of Q2 2023. CytoSorb is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses seen in the ICU and cardiac surgery that can lead to massive inflammation, organ failure, and a high risk of patient death. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively. CytoSorb is also E.U. approved to remove the blood thinners, ticagrelor and rivaroxaban, during cardiothoracic surgery to reduce the risk of perioperative bleeding. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.